You are here
Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.
Wednesday,2015-03-04 12:17 America/Los_Angeles — zdrager
| Title | Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Coresh, J, Turin, TChowdhury, Matsushita, K, Sang, Y, Ballew, SH, Appel, LJ, Arima, H, Chadban, SJ, Cirillo, M, Djurdjev, O, Green, JA, Heine, GH, Inker, LA, Irie, F, Ishani, A, Ix, JH, Kovesdy, CP, Marks, A, Ohkubo, T, Shalev, V, Shankar, A, Wen, CPang, de Jong, PE, Iseki, K, Stengel, B, Gansevoort, RT, Levey, AS |
| Journal | JAMA |
| Volume | 311 |
| Issue | 24 |
| Pagination | 2518-2531 |
| Date Published | 2014 Jun 25 |
| ISSN | 1538-3598 |
| Keywords | Adult, Aged, Aged, 80 and over, Cohort Studies, Creatinine, Disease Progression, Endpoint Determination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Reference Values, Risk |
| Abstract | <p><b>IMPORTANCE: </b>The established chronic kidney disease (CKD) progression end point of end-stage renal disease (ESRD) or a doubling of serum creatinine concentration (corresponding to a change in estimated glomerular filtration rate [GFR] of −57% or greater) is a late event.</p><p><b>OBJECTIVE: </b>To characterize the association of decline in estimated GFR with subsequent progression to ESRD with implications for using lesser declines in estimated GFR as potential alternative end points for CKD progression. Because most people with CKD die before reaching ESRD, mortality risk also was investigated.</p><p><b>DATA SOURCES AND STUDY SELECTION: </b>Individual meta-analysis of 1.7 million participants with 12,344 ESRD events and 223,944 deaths from 35 cohorts in the CKD Prognosis Consortium with a repeated measure of serum creatinine concentration over 1 to 3 years and outcome data.</p><p><b>DATA EXTRACTION AND SYNTHESIS: </b>Transfer of individual participant data or standardized analysis of outputs for random-effects meta-analysis conducted between July 2012 and September 2013, with baseline estimated GFR values collected from 1975 through 2012.</p><p><b>MAIN OUTCOMES AND MEASURES: </b>End-stage renal disease (initiation of dialysis or transplantation) or all-cause mortality risk related to percentage change in estimated GFR over 2 years, adjusted for potential confounders and first estimated GFR.</p><p><b>RESULTS: </b>The adjusted hazard ratios (HRs) of ESRD and mortality were higher with larger estimated GFR decline. Among participants with baseline estimated GFR of less than 60 mL/min/1.73 m2, the adjusted HRs for ESRD were 32.1 (95% CI, 22.3-46.3) for changes of −57% in estimated GFR and 5.4 (95% CI, 4.5-6.4) for changes of −30%. However, changes of −30% or greater (6.9% [95% CI, 6.4%-7.4%] of the entire consortium) were more common than changes of −57% (0.79% [95% CI, 0.52%-1.06%]). This association was strong and consistent across the length of the baseline period (1 to 3 years), baseline estimated GFR, age, diabetes status, or albuminuria. Average adjusted 10-year risk of ESRD (in patients with a baseline estimated GFR of 35 mL/min/1.73 m2) was 99% (95% CI, 95%-100%) for estimated GFR change of −57%, was 83% (95% CI, 71%-93%) for estimated GFR change of −40%, and was 64% (95% CI, 52%-77%) for estimated GFR change of −30% vs 18% (95% CI, 15%-22%) for estimated GFR change of 0%. Corresponding mortality risks were 77% (95% CI, 71%-82%), 60% (95% CI, 56%-63%), and 50% (95% CI, 47%-52%) vs 32% (95% CI, 31%-33%), showing a similar but weaker pattern.</p><p><b>CONCLUSIONS AND RELEVANCE: </b>Declines in estimated GFR smaller than a doubling of serum creatinine concentration occurred more commonly and were strongly and consistently associated with the risk of ESRD and mortality, supporting consideration of lesser declines in estimated GFR (such as a 30% reduction over 2 years) as an alternative end point for CKD progression.</p> |
| DOI | 10.1001/jama.2014.6634 |
| Alternate Journal | JAMA |
| PubMed ID | 24892770 |
| PubMed Central ID | PMC4172342 |
| Grant List | HHSN268201100012C / HL / NHLBI NIH HHS / United States K23 DK067303 / DK / NIDDK NIH HHS / United States U01 DK035073 / DK / NIDDK NIH HHS / United States HHSN268201100010C / HL / NHLBI NIH HHS / United States UL1 RR025005 / RR / NCRR NIH HHS / United States HHSN268201100008C / HL / NHLBI NIH HHS / United States UL1 TR001079 / TR / NCATS NIH HHS / United States K23 DK002904 / DK / NIDDK NIH HHS / United States HHSN268201100007C / HL / NHLBI NIH HHS / United States HHSN268200800007C / HL / NHLBI NIH HHS / United States R01DK100446 / DK / NIDDK NIH HHS / United States N01HC95169 / HL / NHLBI NIH HHS / United States N01 HC025195 / HC / NHLBI NIH HHS / United States HHSN268201100011C / HL / NHLBI NIH HHS / United States UL1 RR024156 / RR / NCRR NIH HHS / United States N01HC55222 / HL / NHLBI NIH HHS / United States N01HC85086 / HL / NHLBI NIH HHS / United States R01 AG007181 / AG / NIA NIH HHS / United States HHSN268201100006C / HL / NHLBI NIH HHS / United States HHSN268201200036C / HL / NHLBI NIH HHS / United States R01 DK031801 / DK / NIDDK NIH HHS / United States R01 HL080295 / HL / NHLBI NIH HHS / United States N01HC85082 / HL / NHLBI NIH HHS / United States HHSN268201100009C / HL / NHLBI NIH HHS / United States N01HC85083 / HL / NHLBI NIH HHS / United States HHSN268201100005C / HL / NHLBI NIH HHS / United States MR/K007017/1 / / Medical Research Council / United Kingdom N01HC85079 / HL / NHLBI NIH HHS / United States MC_PC_13040 / / Medical Research Council / United Kingdom R01 DK100446 / DK / NIDDK NIH HHS / United States R01 HL068140 / HL / NHLBI NIH HHS / United States R01 AG023629 / AG / NIA NIH HHS / United States R01 AG028507 / AG / NIA NIH HHS / United States N01HC85080 / HL / NHLBI NIH HHS / United States CZH/4/656 / / Chief Scientist Office / United Kingdom R01 HL043232-03 / HL / NHLBI NIH HHS / United States N01 HC095159 / HC / NHLBI NIH HHS / United States N01HC85081 / HL / NHLBI NIH HHS / United States |